Headlines about Inovalon (NASDAQ:INOV) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Inovalon earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the technology company an impact score of 46.1343592798613 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Inovalon (NASDAQ INOV) opened at $13.65 on Friday. The firm has a market cap of $1,969.27, a price-to-earnings ratio of 113.76, a PEG ratio of 3.33 and a beta of 1.23. Inovalon has a one year low of $10.45 and a one year high of $17.80. The company has a debt-to-equity ratio of 0.31, a quick ratio of 5.62 and a current ratio of 5.62.
Inovalon (NASDAQ:INOV) last issued its quarterly earnings results on Wednesday, November 1st. The technology company reported $0.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.01. The business had revenue of $115.90 million for the quarter, compared to analysts’ expectations of $114.79 million. Inovalon had a net margin of 4.07% and a return on equity of 4.63%. The company’s revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 EPS. equities research analysts forecast that Inovalon will post 0.25 earnings per share for the current fiscal year.
INOV has been the topic of several research reports. TheStreet upgraded shares of Inovalon from a “d+” rating to a “c-” rating in a report on Thursday, October 5th. Zacks Investment Research upgraded shares of Inovalon from a “sell” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, BidaskClub cut shares of Inovalon from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd. Three research analysts have rated the stock with a sell rating and five have given a hold rating to the stock. Inovalon presently has a consensus rating of “Hold” and a consensus target price of $12.00.
In other news, insider Shauna L. Vernal sold 5,908 shares of Inovalon stock in a transaction on Friday, November 17th. The shares were sold at an average price of $16.01, for a total transaction of $94,587.08. Following the transaction, the insider now owns 47,309 shares in the company, valued at approximately $757,417.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Robert A. Wychulis sold 85,828 shares of the firm’s stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $15.54, for a total transaction of $1,333,767.12. Following the sale, the president now owns 466,286 shares in the company, valued at $7,246,084.44. The disclosure for this sale can be found here. Company insiders own 48.28% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Inovalon (INOV) Given Daily News Impact Score of 0.14” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/20/inovalon-inov-given-daily-news-impact-score-of-0-14.html.
Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.
Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.